News

 

 

Funding: New Awards

New Clinical Trials

Konstantin Dragnev, MD
Member, Cancer Epidemiology and Chemoprevention Research Program at Norris Cotton Cancer Center, and Associate Professor of Medicine; Pharmacology & Toxicology, at Dartmouth Medical School

  • Pfizer
    Phase 3, randomized, open-label study of the efficacy and safety of crizotinib versus pemetrexed/cisplatin or pemetrexed/carboplatin in previously untreated patients with non-squamous carcinoma of the lung harboring a translocation or inversion event involving the anaplastic lymphoma kinase (ALK) gene locus

Marc Ernstoff, MD
Member, Immunology and Cancer Immunotherapy Research Program, and Associate Director for Clinical Research at Norris Cotton Cancer Center, and Professor of Medicine, Dartmouth Medical School

  • ECOG
    A Phase III randomized study of adjuvant ipilimumab anti-CTLA4 therapy versus high-dose interferon a-2b for resected high-risk melanoma
  • CureTech
    Phase II study to evaluate the safety, tolerability and efficacy of CT-011 administered intravenously to patients with metastatic melanoma

Frederick Lansigan, MD
Member, Molecular Therapeutics Research Program at Norris Cotton Cancer Center, and Assistant Professor of Medicine at Dartmouth Medical School

  • PI/Department Funding
    Lipoprotein lipase expression in chronic lymphocytic leukemia
  • PI/Department Funding
    Outcomes of cutaneous T-cell lymphoma and chronic graft-versus-host disease patients treated with extracorporeal photopheresis

Lionel Lewis, MD
Member, Molecular Therapeutics Research Program at Norris Cotton Cancer Center, and Professor of Medicine; Pharmacology & Toxicology, at Dartmouth Medical School

  • Abbott Laboratories
    An extension study of linifanib (ABT-869) in subjects with advanced or metastatic solid tumors (M12-749)

Stephen Liu, MD, MPH
Member, Cancer Control Research Program at Norris Cotton Cancer Center, and Assistant Professor of Medicine at Dartmouth Medical School

  • National Institute on Aging (NIA)
    Exploring the possible association between oral bisphosphonate use and esophageal and gastric cancers

James Rigas, MD
Member, Molecular Therapeutics Research Program at Norris Cotton Cancer Center, and Associate Professor of Medicine at Dartmouth Medical School

  • Sanofi-Avetis
    A prospective, non-interventional, cohort survey on VTE risk in patients receiving new chemotherapy for cancer
  • GlaxoSmithKline Group
    A Phase II, open-label, multicenter, randomized study to assess the efficacy and safety of GSK1120212 compared with docetaxel in 2nd line subjects with targeted mutations (KRAS, NRAS, RAF, MEK1) in locally advanced or metastatic nonsmall cell lung cancer (NSCLC Stage IIIBwet-IV